Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacillus calmette-guerin substrain danish 1331 live antigen
- Development stage
- Phase 4
- Lead developer
- Statens Serum Institut
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravesical, Intradermal
01
Overview
Bacillus calmette-guerin substrain danish 1331 live antigen is a biologic vaccine derived from an attenuated strain of Mycobacterium bovis, specifically the Danish (Copenhagen) 1331 substrain. It is primarily used for the prevention of tuberculosis and as an intravesical immunotherapy for non-muscle invasive bladder cancer. The mechanism of action involves stimulation of the host immune system, leading to enhanced cellular immunity against Mycobacterium tuberculosis or tumor cells in the bladder. The vaccine was originally developed by Albert Calmette and Camille Guérin, with this particular substrain produced and distributed by Statens Serum Institut in Denmark and later AJ Vaccines. Efficacy varies geographically and between different strains, but no significant differences in efficacy have been observed between major strains such as Danish 1331 and Moscow-I[3][5][6].
- Brand names
- BCG SSI
- Other names
- Bacillus Calmette–Guérin Danish 1331BCG Danish 1331Bacillus Calmette–Guérin SSI
Beyond the preview
Go deeper on bacillus calmette-guerin substrain danish 1331 live antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacillus calmette-guerin substrain danish 1331 live antigen.